Drug Patents owned by Cubist Pharms Llc

1. List of Cubicin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(7 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's patent expiration?
More Information on Dosage

2. List of Dificid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(5 months from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jan, 2024

(11 months from now)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(4 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(5 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jan, 2028

(5 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(5 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older; Treatment of microbial infections

Dosage: TABLET;ORAL

How can I launch a generic of DIFICID before it's patent expiration?
More Information on Dosage

3. List of Sivextro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
New Patient Population (NPP) Jun 19, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Zerbaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7129232 CUBIST PHARMS LLC Cephem compounds
May, 2028

(5 years from now)

US8685957 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8476425 CUBIST PHARMS LLC Tazobactam arginine compositions
Sep, 2032

(9 years from now)

US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028963 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US9724353 CUBIST PHARMS LLC Methods for treating intrapulmonary infections
Sep, 2032

(9 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US11278622 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10125149 CUBIST PHARMS LLC Synthesis of cephalosporin compounds
Aug, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2019
New Patient Population (NPP) Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN) Dec 19, 2024

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia; Treatment of complicated urinary tract infection; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Methods of treating bacterial illnesses; Methods for treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in